Sunvozertinib
- Generic Name
- Sunvozertinib
- Indication
用于既往经含铂化疗治疗时或治疗后出现疾病进展，或不耐受含铂化疗，并且经检测确认存在表皮生长因子受体（EGFR）20号外显子插入突变的局部晚期或转移性非小细胞肺癌（NSCLC）的成人患者。
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Tang-Du Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT06864624
- Locations
- 🇨🇳
Tangdu Hospital, Xi'an, Shaanxi, China
Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT06786208
- Locations
- 🇨🇳
Qiming Wang, Zhengzhou, Henan, China
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
- Conditions
- MutationLung Cancer Stage III
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 120
- Registration Number
- NCT06563999
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06355609
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06348927
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 40
- Registration Number
- NCT06195189
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Si Chuan, China
A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT06182761
DZD9008 PK Study in Hepatic Impairment Subjects
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT06084104
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation, San Antonio, Texas, United States
Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT05712902
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, China
🇨🇳Shanxi Provincial Cancer Hospital, Taiyuan, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Pemetrexed+carboplatin
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Dizal Pharmaceuticals
- Target Recruit Count
- 320
- Registration Number
- NCT05668988
- Locations
- 🇺🇸
OPN Healthcare, Inc., Glendale, California, United States
🇺🇸Kaiser Permanente Medical Center, Vallejo, California, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.